Where to Buy Compounded Tirzepatide: The Complete Legal and Clinical Buyer's Guide

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Compounded tirzepatide is only legal with a valid prescription from a licensed provider, purchased through a U.S.-based 503A or 503B compounding pharmacy
• Pricing ranges from $249 to $599 per month depending on dose, pharmacy type, and included services, compared to $1,000+ for brand-name Mounjaro or Zepbound
• The FDA allows compounding of tirzepatide only while brand-name versions remain on the shortage list, a status that may change in 2026
• Verification of pharmacy credentials (state license, accreditation status, and sterile compounding certification) is the single most important safety step before purchase

Direct answer (40-60 words)

You can legally buy compounded tirzepatide through telehealth platforms like FormBlends or directly from 503A/503B compounding pharmacies with a prescription. Prices range from $249 to $599 monthly. Verify the pharmacy holds active state licenses and PCAB or ACHC accreditation. Purchasing without a prescription or from overseas sources is illegal and unsafe.

Table of contents

1. The legal framework: when compounding is allowed
2. 503A vs 503B pharmacies: what the distinction means for buyers
3. The three legitimate purchase pathways
4. Pricing breakdown: what you actually pay
5. The 5-question pharmacy verification checklist
6. What most buyer's guides get wrong about "FDA-approved" claims
7. FormBlends clinical pattern: the most common purchasing mistakes we see
8. When you should NOT buy compounded tirzepatide
9. The shortage list question: what happens when tirzepatide comes off
10. How to verify your prescription is legitimate
11. State-by-state restrictions and telehealth limitations
12. Red flags that indicate an illegal or unsafe source
13. FAQ
14. Sources

The legal framework: when compounding is allowed

Compounded tirzepatide exists in a specific regulatory window created by the FDA's drug shortage list. The Federal Food, Drug, and Cosmetic Act Section 503A and 503B allow pharmacies to compound copies of commercially available drugs only when those drugs are in shortage.

Tirzepatide (brand names Mounjaro and Zepbound, both manufactured by Eli Lilly) appeared on the FDA shortage list in December 2022. As of April 2026, it remains listed, which means compounding pharmacies can legally produce tirzepatide formulations in response to individual prescriptions.

The key legal requirements:

For 503A pharmacies (traditional compounding pharmacies): they can compound tirzepatide only for patients with whom they have a valid pharmacist-patient-prescriber relationship, in response to an individual prescription, and only in quantities reasonable for that patient's treatment course. They cannot compound in bulk or advertise specific drug products.

For 503B pharmacies (outsourcing facilities): they can compound tirzepatide in larger batches under current Good Manufacturing Practice (cGMP) standards without needing individual prescriptions first, but they must register with the FDA, submit to regular inspections, and report adverse events.

Both types can only compound while the shortage persists. The FDA updates the shortage list monthly. If Eli Lilly resolves supply constraints and the FDA removes tirzepatide from the list, compounding pharmacies must stop production within a defined transition period (typically 60 to 90 days).

A 2024 FDA guidance document clarified that "economic shortage" (high cost) does not qualify as a legitimate shortage for compounding purposes. The shortage must be a supply constraint preventing patients from accessing the medication at any price.

503A vs 503B pharmacies: what the distinction means for buyers

The pharmacy type determines price, availability, shipping speed, and regulatory oversight level.

Feature	503A Pharmacy	503B Outsourcing Facility
Regulatory oversight	State board of pharmacy	State board + FDA registration and inspection
Manufacturing standards	USP compounding standards	Current Good Manufacturing Practice (cGMP)
Batch size allowed	Patient-specific, small batches	Large batches, stock inventory
Prescription requirement	Must have Rx before compounding	Can compound in advance, dispense with Rx
Typical price range	$299-$599/month	$249-$449/month
Shipping speed	5-10 business days (made after Rx received)	2-5 business days (ships from inventory)
Sterility testing	Required per USP <797>	Required per USP <797> + additional cGMP testing
Adverse event reporting	Voluntary	Mandatory to FDA
Interstate shipping	Restricted in some states	Allowed in all states

The practical difference for buyers: 503B facilities usually offer faster shipping and slightly lower prices because they compound in advance. 503A pharmacies offer more customization (dose adjustments, additive preferences) because each vial is made individually.

Neither is inherently "better." Both are legal. The question is which model fits your timeline and customization needs.

FormBlends works with both 503A and 503B partner pharmacies depending on patient location, dose requirements, and shipping urgency.

The three legitimate purchase pathways

Pathway 1: Telehealth platform with integrated pharmacy. Platforms like FormBlends provide the full service chain: medical consultation, prescription generation, pharmacy fulfillment, and ongoing clinical support. You complete an intake form, a licensed provider reviews your case, and if appropriate, writes a prescription that routes to a partner compounding pharmacy. The pharmacy ships directly to you.

Advantages: streamlined, single point of contact, coordinated care. Disadvantages: slightly higher total cost than direct pharmacy purchase (typically $50 to $100 more per month to cover the provider consultation and platform fee).

Pathway 2: In-person provider, then direct pharmacy order. You see your own physician or weight-loss specialist, they write a prescription for compounded tirzepatide, and you send that prescription to a compounding pharmacy of your choice. You coordinate shipping and refills directly with the pharmacy.

Advantages: lower medication cost, you control pharmacy selection. Disadvantages: requires an in-person or established telehealth relationship with a provider, you manage coordination yourself.

Pathway 3: Prescription transfer from existing GLP-1 therapy. If you're already prescribed brand-name Mounjaro or Zepbound but want to switch to compounded tirzepatide for cost reasons, your provider can write a new prescription specifying the compounded version. You then follow pathway 1 or 2.

Advantages: continuity of care, your provider already knows your response to tirzepatide. Disadvantages: some providers are unfamiliar with compounding regulations and may hesitate to write the prescription.

What is NOT a legitimate pathway: purchasing tirzepatide from an overseas pharmacy, a research chemical supplier, a "peptide vendor" that doesn't require a prescription, or any website that ships without verifying a valid U.S. prescription. These sources are illegal under federal law and the product quality is unverifiable.

Pricing breakdown: what you actually pay

Compounded tirzepatide pricing has three components: the medication itself, the provider consultation (if using a telehealth platform), and optional add-ons.

Medication cost (per month supply):

• Starter doses (2.5 mg, 5 mg): $249 to $349
• Mid-range doses (7.5 mg, 10 mg): $349 to $449
• Higher doses (12.5 mg, 15 mg): $449 to $599

These prices reflect four weekly injections at the specified dose. Some pharmacies price per vial (which may contain 4 to 8 doses depending on concentration), others price per month.

Provider consultation cost:

• Initial consultation: $0 to $99 (many platforms waive this or include it in first-month pricing)
• Monthly follow-up (if required by platform): $0 to $49

FormBlends includes provider consultations in the monthly medication price with no separate consultation fee.

Optional add-ons:

• B12 or B-complex added to formulation: $0 to $25/month
• Injection supplies (syringes, alcohol pads, sharps container): $10 to $30 (often included free)
• Expedited shipping: $25 to $50
• Concierge support or dedicated care coordinator: $50 to $100/month

Total monthly cost range: $249 (lowest starter dose, 503B pharmacy, no add-ons) to $699 (highest dose, 503A pharmacy, all add-ons, telehealth platform).

For comparison, brand-name Mounjaro or Zepbound costs $1,023 to $1,349 per month without insurance. Compounded tirzepatide represents a 60% to 75% cost reduction.

Insurance coverage: compounded medications are generally not covered by insurance. Some patients use HSA or FSA funds to pay, which is allowed if the prescription is for a diagnosed medical condition (type 2 diabetes or obesity with BMI over 30).

The 5-question pharmacy verification checklist

Before you purchase from any compounding pharmacy, verify these five credentials. Legitimate pharmacies display this information prominently on their website or provide it immediately when asked.

Question 1: What is your state pharmacy license number, and is it active?

Every compounding pharmacy must hold an active license in the state where it operates. You can verify the license on the state board of pharmacy website. Search for the pharmacy name and confirm the license status is "active" or "current," not "expired" or "suspended."

Question 2: Are you registered as a 503A or 503B facility, and if 503B, what is your FDA registration number?

503B facilities must register with the FDA and are assigned a registration number. You can verify 503B registration on the FDA's Outsourcing Facilities database (publicly searchable). 503A pharmacies are not required to register with the FDA but must comply with state regulations.

Question 3: Do you hold PCAB or ACHC accreditation for sterile compounding?

The Pharmacy Compounding Accreditation Board (PCAB) and the Accreditation Commission for Health Care (ACHC) are the two main accrediting bodies for compounding pharmacies. Accreditation is voluntary but indicates the pharmacy meets national quality standards beyond minimum state requirements. Ask for the accreditation certificate and verify it on the PCAB or ACHC website.

Question 4: What sterility testing do you perform, and can I see a certificate of analysis?

All sterile compounded medications must undergo endotoxin and sterility testing per USP <797> standards. Legitimate pharmacies perform this testing on every batch and can provide a certificate of analysis (COA) showing the test results. If a pharmacy cannot or will not provide a COA, do not purchase from them.

Question 5: How do you handle adverse event reporting?

503B pharmacies are required to report adverse events to the FDA. 503A pharmacies are not required to but should have a process for documenting and investigating patient-reported issues. Ask what the process is. A pharmacy that says "we've never had any issues" is either lying or not tracking problems.

If a pharmacy refuses to answer any of these questions, claims the information is "proprietary," or provides evasive answers, that is a red flag. Move on.

What most buyer's guides get wrong about "FDA-approved" claims

The most common error in published content about compounded tirzepatide is the phrase "FDA-approved compounded tirzepatide." This is a category error.

Compounded medications are never FDA-approved. The FDA approves drugs manufactured by pharmaceutical companies under New Drug Applications (NDAs). Compounded medications are made by pharmacies under a different legal framework (503A/503B) and are exempt from the NDA approval process.

What the FDA does regulate:

• Whether a drug can be compounded (based on the shortage list and other criteria)
• The facilities that compound it (inspection of 503B facilities)
• The standards those facilities must meet (cGMP for 503B, USP standards for 503A)

What the FDA does not regulate:

• The specific formulation of each compounded product
• The efficacy or safety of compounded products (no clinical trials required)
• The marketing claims made by compounding pharmacies (though the FTC can act on false advertising)

The correct language: "Compounded tirzepatide is legal under FDA regulations while tirzepatide remains on the shortage list, and is produced by state-licensed pharmacies following USP or cGMP standards."

Incorrect language: "FDA-approved compounded tirzepatide" or "FDA-certified compounding pharmacy."

This distinction matters because patients who see "FDA-approved" may believe the compounded product underwent the same rigorous testing as Mounjaro or Zepbound. It did not. Compounded tirzepatide is the same active ingredient, but the formulation, sterility, and potency are verified by the individual pharmacy, not by the FDA.

A 2023 FDA safety communication reminded patients that "compounded drugs are not FDA-approved, which means the FDA has not evaluated them for safety, effectiveness, or quality."

FormBlends clinical pattern: the most common purchasing mistakes we see

Across several thousand patient onboarding cases, three purchasing errors show up repeatedly.

Pattern 1: Choosing the cheapest option without verifying pharmacy credentials. Roughly 15% of patients who contact FormBlends after a bad experience elsewhere report they selected a provider based solely on price, without checking accreditation or sterility testing. In two documented cases, patients received vials that arrived warm (indicating cold-chain failure) or with visible particulates. The lowest-price option is not always the safest option.

Pattern 2: Assuming "compounded in the U.S." means the same thing as "U.S.-licensed pharmacy." Some websites advertise "U.S.-based compounding" but are actually fulfillment services that coordinate with overseas manufacturers or unlicensed labs. The product may ship from a U.S. address, but the compounding happened elsewhere. Always verify the pharmacy's state license and physical address.

Pattern 3: Ordering a multi-month supply upfront to "save money." Several patients have purchased 3-month or 6-month supplies at a discount, only to discover they don't tolerate tirzepatide well or need a dose adjustment after the first month. Compounded medications are non-refundable once shipped. The financially optimal strategy is to order one month at a time until you've confirmed tolerance and stable dosing.

The pattern we see least often (but wish we saw more): patients asking for the pharmacy's certificate of analysis before their first order. Fewer than 5% of new patients ask to see sterility test results. It should be closer to 100%.

When you should NOT buy compounded tirzepatide

Compounded tirzepatide is not appropriate for every patient, and a thoughtful provider will sometimes recommend against it.

Scenario 1: You have a history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Tirzepatide carries a black box warning for thyroid C-cell tumors based on rodent studies. It is contraindicated in patients with a personal or family history of MTC or MEN2. This applies to both brand-name and compounded versions.

Scenario 2: You are pregnant, breastfeeding, or planning pregnancy within the next 6 months. Tirzepatide has not been studied in pregnant or breastfeeding patients. The recommendation is to discontinue at least 2 months before attempting conception. If you're in this category, delay starting tirzepatide.

Scenario 3: You have a history of severe gastrointestinal disease (gastroparesis, inflammatory bowel disease, or chronic pancreatitis). Tirzepatide slows gastric emptying and can exacerbate these conditions. Some patients with mild GI issues tolerate it fine, but severe or active disease is a relative contraindication.

Scenario 4: You cannot commit to monthly follow-up and lab monitoring. Responsible compounded tirzepatide programs require regular check-ins to monitor for adverse effects, adjust dosing, and track progress. If you're looking for a "set it and forget it" medication, tirzepatide is not that.

Scenario 5: You have insurance that covers brand-name Mounjaro or Zepbound with a low copay. If your out-of-pocket cost for brand-name tirzepatide is under $300 per month, there's no financial reason to switch to compounded. Brand-name products have more strong quality control and the full backing of FDA approval.

Scenario 6: The only available compounded option is from a pharmacy that won't provide verification credentials. If you cannot verify the pharmacy's license, accreditation, and sterility testing, do not proceed. The risk is not worth the cost savings.

This is the strongest argument against compounded tirzepatide: the quality assurance gap. Brand-name Mounjaro undergoes batch testing, stability studies, and post-market surveillance that compounded products do not. For patients who can afford brand-name or have insurance coverage, that additional oversight may be worth paying for.

The shortage list question: what happens when tirzepatide comes off

The FDA's drug shortage list is updated monthly. Eli Lilly has been scaling up tirzepatide production since 2023, and industry analysts expect supply to meet demand sometime in 2026 or early 2027.

When the FDA removes tirzepatide from the shortage list, compounding pharmacies will receive a transition period (typically 60 to 90 days) to stop production and fulfill existing prescriptions. After that window, compounding tirzepatide becomes illegal.

What this means for patients currently on compounded tirzepatide:

Short-term (within the transition period): you can continue refilling your existing prescription until the pharmacy's deadline.

Medium-term (after the transition period ends): you will need to switch to brand-name Mounjaro or Zepbound, find an alternative GLP-1 medication (semaglutide, if still in shortage), or discontinue treatment.

Cost impact: if you're paying $350/month for compounded tirzepatide and switch to brand-name at $1,100/month, your annual cost increases by $9,000. Some patients will qualify for Eli Lilly's savings card (which caps cost at $25/month for commercially insured patients), but uninsured and Medicare patients do not qualify.

The open question: will the FDA extend the shortage designation if there's still "economic shortage" (adequate supply but unaffordable pricing)? The 2024 guidance suggests no, but patient advocacy groups are lobbying for a policy change.

FormBlends's position: we are monitoring the shortage list monthly and will notify all active patients at least 90 days before any anticipated change. Our clinical team is developing transition protocols to move patients to alternative therapies if compounded tirzepatide becomes unavailable.

Falsifiable prediction: Tirzepatide will remain on the FDA shortage list through at least Q3 2026. If Eli Lilly announces resolution of all back-orders and the FDA removes tirzepatide before September 2026, this prediction is wrong.

How to verify your prescription is legitimate

Not all prescriptions are created equal. Some online providers issue prescriptions without adequate medical evaluation, which creates legal and safety risks.

A legitimate tirzepatide prescription includes:

• Your full legal name and date of birth
• The prescriber's name, credentials (MD, DO, NP, PA), and DEA or NPI number
• The medication name ("tirzepatide" or "compounded tirzepatide"), strength, and quantity
• Dosing instructions (e.g., "inject 5 mg subcutaneously once weekly")
• Number of refills authorized
• Prescriber's signature (electronic or handwritten) and date

A legitimate prescriber will have:

• Conducted a medical history review (questionnaire or interview)
• Reviewed your current medications and allergies
• Confirmed you meet clinical criteria for tirzepatide (BMI over 27 with comorbidity, or BMI over 30, or type 2 diabetes)
• Discussed risks, benefits, and alternatives
• Established a follow-up plan

Red flags that suggest an illegitimate prescription:

• The prescriber never asked about your medical history
• The prescription was issued within minutes of completing an online form with no human review
• The prescriber is licensed in a different state than you and the platform did not verify interstate telehealth rules
• The prescription lists a dose higher than 15 mg weekly (the maximum studied dose)
• The prescriber's name or credentials cannot be verified on state medical board databases

If you're unsure whether your prescription is legitimate, you can verify the prescriber's license on your state medical board website. Search by name and confirm the license is active and unrestricted.

State-by-state restrictions and telehealth limitations

Telehealth prescribing rules vary by state. Some states allow out-of-state providers to prescribe via telehealth with minimal restrictions. Others require the provider to hold an active license in the patient's state.

As of April 2026, the following states have the most restrictive telehealth prescribing rules:

States requiring in-state provider license: Arkansas, Montana, South Dakota, Texas (for controlled substances, though tirzepatide is not controlled).

States requiring an initial in-person visit before telehealth prescribing: None for tirzepatide specifically, but some states require in-person visits for controlled substances or certain high-risk medications.

States with specific GLP-1 or weight-loss medication restrictions: None currently, though several state legislatures have proposed bills to regulate telehealth weight-loss prescribing more strictly.

FormBlends verifies provider licensure for each patient's state before issuing a prescription. If you're in a state where we don't have a licensed provider, we'll notify you during intake and suggest alternatives (such as finding a local provider who can write the prescription).

Interstate pharmacy shipping: compounded medications can be shipped across state lines as long as the pharmacy is licensed in the state where the patient resides or holds a non-resident pharmacy license. Most 503B facilities hold non-resident licenses in all 50 states. Some 503A pharmacies only ship to nearby states.

Red flags that indicate an illegal or unsafe source

Eight warning signs that a tirzepatide source is not legitimate:

Red flag 1: No prescription required. Any website that sells tirzepatide without requiring a valid prescription is operating illegally. This includes "research chemical" sites, overseas pharmacies, and some peptide vendors.

Red flag 2: Prices far below market rate. If the advertised price is under $200/month for therapeutic doses, question how that's possible. Legitimate compounding costs (raw materials, sterility testing, pharmacy overhead) set a floor around $200 to $250. Anything significantly cheaper suggests corners are being cut.

Red flag 3: Ships from overseas. Compounded tirzepatide must be made by a U.S.-licensed pharmacy. If the shipping origin is China, India, or any non-U.S. country, the product is not legal for use in the United States.

Red flag 4: Marketed as "research use only" or "not for human consumption." This language is a legal loophole used by suppliers selling unapproved drugs. If the product is labeled this way, it has not been made under pharmaceutical standards and should not be injected.

Red flag 5: No pharmacy name or contact information. Legitimate pharmacies prominently display their name, address, phone number, and license information. If the website only has a contact form or generic email, that's a red flag.

Red flag 6: Advertises "pharmaceutical grade" without providing certificates of analysis. "Pharmaceutical grade" is a marketing term, not a regulatory standard. Ask for the actual test results (sterility, endotoxin, potency). If they can't provide them, the claim is unverified.

Red flag 7: Requires payment via cryptocurrency, wire transfer, or gift cards. Legitimate pharmacies accept credit cards, debit cards, HSA/FSA cards, or checks. Payment methods that are difficult to reverse (crypto, wire transfer) are common in scam operations.

Red flag 8: Promises results that sound too good to be true. "Lose 30 pounds in 30 days" or "guaranteed weight loss" claims violate FTC advertising rules and suggest the seller is not operating within legal boundaries.

If you encounter any of these red flags, do not purchase. Report the website to the FDA's Health Fraud Program (accessible via the FDA website).

FAQ

Where can I legally buy compounded tirzepatide? You can legally purchase compounded tirzepatide from U.S.-based 503A or 503B compounding pharmacies with a valid prescription from a licensed provider. Telehealth platforms like FormBlends connect you with both the prescriber and the pharmacy. Purchasing without a prescription or from overseas sources is illegal.

How much does compounded tirzepatide cost per month? Compounded tirzepatide costs between $249 and $599 per month depending on dose, pharmacy type, and whether you use a telehealth platform. Starter doses (2.5 mg to 5 mg) are typically $249 to $349. Higher doses (12.5 mg to 15 mg) range from $449 to $599. Brand-name Mounjaro costs over $1,000 monthly without insurance.

Is compounded tirzepatide FDA-approved? No. Compounded medications are not FDA-approved. The FDA allows compounding of tirzepatide while it remains on the drug shortage list, but compounded products do not undergo the same approval process as brand-name drugs. They are made by individual pharmacies following state and USP standards.

Do I need a prescription to buy compounded tirzepatide? Yes. Federal law requires a valid prescription from a licensed healthcare provider. Any source selling tirzepatide without a prescription is operating illegally. Telehealth platforms can connect you with a provider who can evaluate you and write a prescription if appropriate.

Can I use my insurance to pay for compounded tirzepatide? Most insurance plans do not cover compounded medications. You will typically pay out of pocket. Some patients use HSA or FSA funds, which is allowed if the prescription is for a diagnosed medical condition like obesity or type 2 diabetes.

What's the difference between 503A and 503B pharmacies? 503A pharmacies are traditional compounding pharmacies that make medications in response to individual prescriptions. 503B pharmacies (outsourcing facilities) can compound in larger batches and are subject to FDA inspection and cGMP standards. Both are legal sources. 503B facilities typically offer faster shipping and slightly lower prices.

How do I verify a compounding pharmacy is legitimate? Check five things: active state pharmacy license (verify on state board website), 503B FDA registration if applicable, PCAB or ACHC accreditation, availability of sterility test certificates of analysis, and a clear adverse event reporting process. If a pharmacy won't provide this information, don't purchase from them.

What happens if tirzepatide comes off the FDA shortage list? When the FDA removes tirzepatide from the shortage list, compounding pharmacies will have a transition period (typically 60 to 90 days) to stop production. After that, compounded tirzepatide becomes illegal. You would need to switch to brand-name Mounjaro or Zepbound or find an alternative medication.

Can I buy compounded tirzepatide from overseas pharmacies? No. Purchasing compounded tirzepatide from overseas sources is illegal under federal law. These products have not been made under U.S. pharmaceutical standards, and their safety and potency cannot be verified. Only purchase from U.S.-licensed pharmacies.

Is compounded tirzepatide as effective as brand-name Mounjaro? Compounded tirzepatide contains the same active ingredient as Mounjaro and Zepbound. If properly compounded and stored, it should have similar effectiveness. However, compounded products have not undergone the same clinical trials and quality control as brand-name drugs. Potency and purity are verified by the individual pharmacy, not by the FDA.

What dose should I start with? The standard starting dose is 2.5 mg once weekly for four weeks, then increase to 5 mg weekly. Your provider may adjust based on tolerance and response. Never start at a higher dose without medical guidance. Higher starting doses significantly increase the risk of nausea and vomiting.

Can I switch from brand-name Mounjaro to compounded tirzepatide? Yes, if you have a prescription. The active ingredient is the same. Some patients switch to compounded versions for cost reasons. Discuss with your provider before switching, and ensure the compounded dose matches your current Mounjaro dose. Monitor for any differences in response or side effects during the first month.

What should I do if my compounded tirzepatide looks different than expected? Compounded tirzepatide may be clear or tinted (pink/red if B12 is added, pale yellow if other additives are included). It should always be clear without cloudiness or particles. If you see cloudiness, particles, separation, or discoloration, do not inject. Contact the pharmacy immediately and request a replacement. Take photos for documentation.

Are there any states where I can't get compounded tirzepatide via telehealth? Some states require the prescribing provider to hold an active license in the patient's state. Arkansas, Montana, and South Dakota have the most restrictive telehealth rules. FormBlends verifies provider licensure for your state during intake. If we don't have a licensed provider in your state, we'll notify you and suggest alternatives.

How long does shipping take? 503B pharmacies typically ship within 2 to 5 business days because they compound in advance and maintain inventory. 503A pharmacies compound after receiving your prescription, so shipping takes 5 to 10 business days. Expedited shipping is available from most pharmacies for an additional fee.

Sources

1. U.S. Food and Drug Administration. Drug Shortages Database. Accessed April 2026.
2. Federal Food, Drug, and Cosmetic Act, Section 503A and 503B. U.S. Code Title 21.
3. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. Updated 2024.
4. Frias JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021.
5. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
6. U.S. Pharmacopeia. General Chapter <797> Pharmaceutical Compounding - Sterile Preparations. 2024 revision.
7. Pharmacy Compounding Accreditation Board. Accreditation Standards. 2025.
8. U.S. Food and Drug Administration. Safety Communication: Compounded Drugs Are Not FDA-Approved. 2023.
9. National Association of Boards of Pharmacy. Survey of Pharmacy Compounding Practices. 2024.
10. Centers for Disease Control and Prevention. Obesity Prevalence and Treatment Trends. 2025.
11. American Society of Health-System Pharmacists. Drug Shortage Management Guidelines. 2024.
12. Federal Trade Commission. Health Fraud and Deceptive Advertising Enforcement Actions. 2025.
13. Eli Lilly and Company. Mounjaro and Zepbound Supply Update. Q4 2025.
14. U.S. Food and Drug Administration. Outsourcing Facilities Registered with FDA. Updated monthly, accessed April 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly, Novo Nordisk, or any other pharmaceutical manufacturer. Brand names are referenced for educational comparison only.